These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25093771)

  • 1. The response of psychotic symptoms in a patient with resistant schizophrenia under treatment of high-dose risperidone long-acting injection.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2014; 26(3):E16-7. PubMed ID: 25093771
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
    Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
    J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting injectable risperidone as an option in first-episode psychosis.
    Covell NH
    Evid Based Ment Health; 2016 May; 19(2):e8. PubMed ID: 27073212
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDR1 gene polymorphisms and response to acute risperidone treatment.
    Kastelic M; Koprivsek J; Plesnicar BK; Serretti A; Mandelli L; Locatelli I; Grabnar I; Dolzan V
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):387-92. PubMed ID: 20060871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
    Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
    J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis.
    Kimura H; Kanahara N; Watanabe H; Iyo M
    Schizophr Res; 2013 Apr; 145(1-3):130-1. PubMed ID: 23403411
    [No Abstract]   [Full Text] [Related]  

  • 11. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study.
    Di Fiorino M; Montagnani G; Trespi G; Kasper S
    Int Clin Psychopharmacol; 2014 May; 29(3):166-76. PubMed ID: 24681810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of risperidone in psychosis associated with Huntington's disease.
    Madhusoodanan S; Brenner R
    Am J Geriatr Psychiatry; 1998; 6(4):347-9. PubMed ID: 9793585
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of risperidone treatment for BPSD.
    Snowdon J; Brodaty H; Ames D; Day S
    Int J Geriatr Psychiatry; 2006 Jul; 21(7):699-701. PubMed ID: 16821255
    [No Abstract]   [Full Text] [Related]  

  • 16. New for old? Risperidone long-acting injection in older patients.
    Hudson-Jessop P; Hughes B; Brinkley N
    Australas Psychiatry; 2007 Dec; 15(6):461-4. PubMed ID: 17999255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms.
    Johnston TG
    Int Clin Psychopharmacol; 2011 Mar; 26(2):114-9. PubMed ID: 21119522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone treatment for psychosis in end-stage Friedreich's ataxia.
    Salbenblatt MJ; Buzan RD; Dubovsky SL
    Am J Psychiatry; 2000 Feb; 157(2):303. PubMed ID: 10671420
    [No Abstract]   [Full Text] [Related]  

  • 19. [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy].
    Sárosi A
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):179-87. PubMed ID: 17211053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.
    Barteček R; Juřica J; Zrůstová J; Kašpárek T; Pindurová E; Žourková A
    Neuro Endocrinol Lett; 2012; 33(2):236-44. PubMed ID: 22592207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.